Accidental natalizumab administration to the third trimester of pregnancy in an adolescent patient with multiple sclerosis

Acta Neurologica Scandinavica

Volumn 126, Issue 1, 2012, Pages

  Henderson, C E ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NATALIZUMAB;

ADOLESCENT; DRUG USE; DRUG WITHDRAWAL; EMBRYO DEVELOPMENT; HUMAN; LETTER; MULTIPLE SCLEROSIS; ORGANOGENESIS; REGISTER; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; THIRD TRIMESTER PREGNANCY;

ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 84861958653     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2011.01637.x     Document Type: Letter

References (3)

1. Bayas A, Penzien J, Hellwig K. Accidental natalizumab administration to the third trimester of pregnancy in an adolescent patient with multiple sclerosis. Acta Neurol Scand 2011;124:290-2.
2. Singh S, Sedgh G, Hussain R. Unintended pregnancy: worldwide levels, trends, and outcomes. Stud Fam Plann 2010;41:231-49.
3. Cristiano L, Bozic c, Bloomgren g. Preliminary evaluation of pregnancy outcomes from the TYSABRI (Natalizumab) pregnancy exposure registry. AAN 2010; Abstract P01.185.